Ann: Novogen Appoints Dr James Garner as New CEO, page-29

That's another angle GF - and it makes sense. The beauty of Novogen is that all the preliminary hard work has been done (as far as I can imagine anyway) and the chances of failure in the short term at least have been minimalized.

So not a lot of downside in 2016 and if the results start to look spectacular he gets to ride that. He might be betting that could fast track him to a higher position than before into a big pharma.

You could be right.